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The risk of developing cancer should theoretically
increase with both the number of cells and the
lifespan of an organism. However, gigantic animals do
not get more cancer than humans, suggesting that
super-human cancer suppression has evolved
numerous times across the tree of life. This is the
essence and promise of Peto’s Paradox. We discuss
what is known about Peto’s Paradox and provide
hints of what is yet to be discovered.risk of cancer does not correlate with increased bodyWhat is Peto’s Paradox?
Peto’s Paradox is named after epidemiologist Richard
Peto, who noted the relationship between time and
cancer when he was studying how tumors form in mice.
Peto observed that the probability of cancer progression
was related to the duration of exposure to the carcino-
gen benzpyrene [1]. He later added body mass to the
equation, when he wondered why humans both contain
1000 times more cells and live 30 times longer than
mice, yet the two species do not suffer incredibly differ-
ent probabilities of developing cancer [2]. Further,
cancer was not a major cause of mortality for large and
long-lived wild animals, despite the increased theoretical
risks. How can this be?Why is it a paradox?
In a multicellular organism, cells must go through a cell
cycle that includes growth and division. Every time a
human cell divides, it must copy its six billion base pairs
of DNA, and it inevitably makes some mistakes. These
mistakes are called somatic mutations. Some somatic
mutations may occur in genetic pathways that control
cell proliferation, DNA repair, apoptosis, telomere ero-
sion, and growth of new blood vessels, disrupting the* Correspondence: maley@asu.edu
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division carries a certain chance that a cancer-causing
somatic mutation could occur, then the risk of develop-
ing cancer should be a function of the number of cell
divisions in an organism’s lifetime [4]. Therefore, large
bodied and long-lived organisms should face a higher
lifetime risk of cancer simply due to the fact that their
bodies contain more cells and will undergo more cell
divisions over the course of their lifespan (Fig. 1). How-
ever, a 2015 study that compared cancer incidence from
zoo necropsy data for 36 mammals found that a higher
mass or lifespan [5]. In fact, the evidence suggested that
larger long-lived mammals actually get less cancer. This
has profound implications for our understanding of how
nature has solved the cancer problem over the course of
evolution.How does one go about solving the paradox?
From one perspective, the solution to Peto’s Paradox is
quite simple: evolution [6]. When individuals in popula-
tions are exposed to the selective pressure of cancer risk,
the population must evolve cancer suppression as an
adaptation or else suffer fitness costs and possibly
extinction. But that only tells us that evolution has
found a solution to the paradox, not how those animals
are suppressing cancer. Discovering the mechanisms
underlying these solutions to Peto’s Paradox requires the
tools of numerous subfields of biology including genom-
ics, comparative methods, and experiments with cells.
For instance, genomic analyses revealed that the African
savannah elephant (Loxodonta africana) genome con-
tains 20 copies, or 40 alleles, of the most famous tumor
suppressor gene TP53 [5, 7]. The human genome
contains only one TP53 copy, and two functional TP53
alleles are required for proper checks on cancer progres-
sion. When cells become stressed and incur DNA
damage, they can either try to repair the DNA or they
can undergo apopotosis, or self-destruction. The protein
produced by the TP53 gene is necessary to turn on thisis distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
ro/1.0/) applies to the data made available in this article, unless otherwise stated.
Fig. 1. An illustration of Peto’s Paradox. Cancer is a disease of uncontrolled cell growth and division, and the risk of developing cancer increases with the
number of cell divisions during the lifetime of an organism. Thus, the expected cancer rate for large and/or long-lived species is higher than for smaller
short-lived ones. The solid red line indicates a linear relationship between cancer rate and (body mass)*(lifespan) and the dashed red line represents an
approximation of the expected cancer rate assuming a model describing the probability of an individual developing colorectal cancer after a given
number of cell divisions [4]. The solid blue line represents the observation that there is no relationship between cancer risk and (body mass)*(lifespan) [5].
For instance, cancer risk, which is 11–25% in the human population, is not vastly different between mice and humans. In contrast, cancer risk was
estimated to be 5% in elephants [5]. Metastatic cancer was found in a duck-billed dinosaur [26], suggesting cancer was common enough in that lineage
to be preserved in the fossil record, but not in other species of large dinosaurs. While adult body mass is approximately the same for the dinosaur and
the elephant, duck-billed dinosaurs are thought to have had a shorter lifespan [28, 31]. This suggests that the trade-offs between reproduction and
growth and cancer defense mechanisms [22] left these dinosaurs more susceptible to cancer than elephants
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allele have Li Fraumeni syndrome and a ~90% lifetime
risk of many cancers, because they cannot properly shut
down cells with DNA damage. Meanwhile, experiments
revealed that elephant cells exposed to ionizing radiation
behave in a manner consistent with what you would
expect with all those TP53 copies—they are much more
likely to switch on the apoptotic pathway and therefore
destroy cells rather than accumulate carcinogenic
mutations [5, 7].
How many different solutions to Peto’s Paradox
are there?
There are likely many solutions to Peto’s Paradox in na-
ture, because large body size has evolved independently
so many times across the history of life. We know that
whales did not evolve the extra copies of TP53 like
elephants [8, 9]. In fact, there is no evidence that whales
evolved extra copies of any tumor suppressor gene—e-
ven the gigantic bowhead whale (Balaena mysticetus),which has a lifespan of over 200 years [9]. In popula-
tions, large body size is often associated with higher
fitness, conferring greater access to resources or mates
and better predator avoidance. It is not surprising, there-
fore, that large body size has evolved again and again
throughout evolutionary time—a trend first realized in
the fossil record and known as Cope’s Rule [10]. Cope’s
Rule applies widely across life from diverse marine taxa
[11] to the extinct giant dinosaurs [12]. Large body size
has evolved independently in 10 of the 11 placental
mammalian orders [13]: think polar bears and hippopot-
ami, walruses and giraffes, elephants and whales. Since
many lineages faced the trade-off between large body
size and cancer risk during their evolution, there have
likely been many different pathways in which cancer
suppression has evolved.
What solutions to the paradox do we know?
In the example of the elephant given above, greater
tumor suppressor gene redundancy provides better
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DNA damage and preventing cancer [5, 7]. Larger ani-
mals have a lower metabolic rate than smaller ones, and
the mutagenic agents supplied by fast metabolisms—-
most notably reactive oxygen species that can damage
DNA—are simply less common in large animals. This
may also resolve Peto’s Paradox in some species. Some
exceptionally long-lived rodents such as naked mole rats
and blind mole rats are famous for having very low can-
cer rates. In the case of naked mole rats (Heterocephalus
glaber), this seems to be due to a form of hyaluronic
acid and a super-sensitive CDKN2A tumor suppressor
pathway that suppresses proliferation of naked mole rat
cells [14, 15]. Blind mole rats (Spalax judaei and Spalax
golani) have a different mechanism of cancer suppres-
sion. Over-proliferation of blind mole rat cells triggers
massive necrotic cell death that destroys both the prolif-
erating cells and their neighbors [16].
There are a variety of hypotheses for other potential
solutions to Peto’s Paradox. One attractive hypothesis is
the prediction of ‘hypertumors’ [17]: bigger tumors in
bigger animals take longer to grow and are susceptible
to ‘cheater’ cells, which can take advantage of the tu-
mor’s angiogenic properties and lower the fitness of the
whole tumor. The effect of hypertumors could be to
lower the overall lethality of cancer in the bodies of large
animals. Other potential solutions could be: large ani-
mals have increased immunocompetence with better
surveillance and attacking of neoplastic cells, or they
may have shorter telomeres which would limit the num-
ber of cell divisions and thus the risk of cancer. How-
ever, these solutions have not yet been observed in
large-bodied species and more research in these areas is
needed.How can you translate a solution in some other
species to prevent cancer in humans?
Ideally, comparative studies could highlight potential tar-
gets where the genetic mechanisms underlying cancer
suppression in one species could be transferred to an-
other, with clinical implications. For instance, it was
found that genetically altering mice to overexpress a
form of the TP53 protein conferred a cancer-suppressive
phenotype; however, these mice also displayed a prema-
ture ageing phenotype [18]. Surprisingly, another study
created ‘super p53’ mice which contained extra copies of
the TP53 gene—similar to the elephant genome—under
their normal promoters, and these mice revealed an en-
hanced DNA damage response and cancer suppression
without the ageing effect [19]. Work is now underway to
develop medicines based on the TP53 pathway. While
the search for solutions to Peto’s Paradox across a diver-
sity of species is still in progress [5, 7, 9, 20], it will nodoubt require substantial effort to translate recent dis-
coveries into effective therapies for humans.
But wait, why haven’t all animals evolved extra
tumor suppression mechanisms?
Cancer is a potential problem for all multicellular life
and there is no expectation that a species should be
completely cancer free; in fact, elephants still get can-
cer—about 5% of deaths in zoos according to one study
[5]. Cancer has also been found in whales [21]. There
are a few potential reasons that cancer is still a problem
for multicellular animals. First, cancer defense mecha-
nisms, such as DNA repair, cell cycle control, and im-
mune function, can be costly. There are likely energetic
trade-offs between cancer suppression and other import-
ant life history components, such as reproduction and
growth [22]. Cancer is a disease of ageing populations
both because there is weaker selection to avoid problems
after reproduction [23], and because it takes time to ac-
cumulate all the mutations necessary to cause a cancer.
For animals that are short-lived (such as mice), it doesn’t
make much sense to invest much in cancer defense
mechanisms. These animals are more likely to die of
other extrinsic causes (such as predators) than of cancer.
Second, benefits early in life that increase an organism’s
fitness may lead to disease susceptibility later in life, an
evolutionary term called antagonistic pleiotropy [24].
For example, there may be a genetic variant that allows
an organism to get big fast—increasing its mating poten-
tial and decreasing the likelihood it will be killed by a
predator—but this same genetic variant may also lead to
cancer susceptibility as the animal ages.
Did dinosaurs get cancer?
Birds evolved from a lineage of theropod dinosaurs dur-
ing the Jurassic Period and they get cancer today [20], so
we can say that, yes, absolutely, dinosaurs did and still
do get cancer. Cancer incidence in extant birds is lower
than in mammals [25], and the reasons for this are not
well known and are worthy of future study. There is a
fossil record of cancer for extinct non-avian dinosaurs as
well; one study examined >10,000 vertebrae from >700
individuals across the dinosaur phylogeny [26]. The
study concluded that the only examined non-avian dino-
saurs with bone neoplasms were large, elephant-sized
herbivores classified as hadrosaurs, also known as duck-
billed dinosaurs, including one instance of metastatic
cancer in a caudal vertebrae (tail bone) from an individ-
ual Edmontosaurus. A later study described a set of be-
nign neoplasms in a titanosaur [27], which was a
member of the sauropod family that included the largest
terrestrial animals in Earth’s history. Whether the exclu-
sivity of non-avian dinosaurian malignant cancers to
hadrosaurs is due to a genetic component or some
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ever, similar sample sizes across many dinosaur clades
were examined, so it appears to be statistically signifi-
cant, and cancer may have occurred often enough in
hadrosaurs so that some affected individuals became fos-
silized and eventually observed by paleontologists.
Why did hadrosaurs get so much cancer but not
other large dinosaurs?
The answer may lie in life history differences. Elephants
have slow life histories, taking decades to reach adult
size and investing heavily in the rearing of their off-
spring. It makes sense that natural selection led to the
evolution of elephants with a means to suppress cancer,
because only those that could suppress cancer lived long
enough and grew large enough to out-compete their ri-
vals. Can we apply this logic to extinct dinosaurs? The
fact that one out of 16 Edmontosaurus specimens had
metastatic cancer [26] suggests that cancer occurred at a
rate sufficient to ensure preservation in the fossil record.
Fortunately, some species of hadrosaur—including
Edmontosaurus—left behind rich fossil deposits, giving
paleontologists a window into hadrosaurian demograph-
ics [28, 29]. Hadrosaurs lived very different lives to our
extant mammalian giants. They laid many eggs at a time
in huge nests, suggesting greater reproductive output,
and grew very rapidly, with some species reaching skel-
etal maturity in as little as 8 years. In addition, hadro-
saurs may have had much shorter lifespans than modern
gigantic mammals, with senescence beginning soon after
skeletal maturity and some fossil deposits lacking any
adults over ~16 years of age [28]. High reproductive out-
put, rapid growth rates, and large body sizes may have
been traits necessary for species survival during the Late
Cretaceous Period ~70 million years ago, when preda-
tors like tyrannosaurs roamed the ancient floodplains.
Perhaps the trade-offs associated with these traits, such
as lack of sufficient DNA repair mechanisms [22], left
hadrosaurs susceptible to cancer once reaching a certain
size. Other large dinosaurs may have had slower life his-
tory strategies and so were under selection to evolve
more effective cancer suppression mechanisms.
Why should I care about Peto’s Paradox?
If cancer suppression has repeatedly evolved as a trait,
then basic research into the life history, genomics, and
cell biology of many different organisms can ultimately
lead to better therapeutic strategies. If Peto’s Paradox
holds across the tree of life, and large long lived organ-
isms do in fact get less cancer than their body size war-
rants, then it implies numerous mechanisms exist to
prevent neoplastic progression and battle cancer. Every
time we discover a potential mechanism for cancer sup-
pression in a species, there is the chance that we canfind new therapeutic targets and approaches to cancer
prevention to save human lives. Cancer has been part of
the story of the evolution of multicellularity [29], and it
is obvious that many lineages have evolved ways to cope
with this disease. Now we are living in the midst of
Earth’s sixth mass extinction, with extinction rates pos-
sibly 1000 times the historical rate [30]. Investigations
into Peto’s Paradox can help cancer prevention research
as well as foster an appreciation for biodiversity and the
need to conserve species across the planet.
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